It's the monetary policy equivalent of Sherlock Holmes's "curious incident" of the dog that didn't bark in the night
The fast-food Tex-Mex chain’s breakfast campaign recalls a series of Jack in the Box ads from more than a decade ago
His chief plaint seems to be that Staples outposts wouldn't be staffed by union members
Venture capital fundraising is on the rise in the first quarter, while stocks from Facebook, Twitter, and others have dropped in recent weeks
After five years of trying to keep banks from all failing together, now we have to worry about asset managers?
Even Thomas Edison and Leonardo da Vinci benefited from collaboration
Kevin Costner's latest sports flick, Draft Day, suggests that the front office is where the real action happens
He's trying to "improve his résumé," says his lawyer
Alabama Republican Jeff Sessions wants the SBA to share more data on loan defaults that put taxpayer money at risk
Founders: Dr. Samir Patel and Dr. David Guyer
VC Investment over the last four quarters: $37.47 million
Founded in 2007, the 15-employee Ophthotech is a biotech company developing treatments for age-related macular degeneration, a common cause of vision loss in older adults. The co-founders' prior venture, Eyetech, was acquired by OSI Pharmaceuticals (OSIP) in 2005 in a deal valued at $900 million.
Key to startup success: "[Our] in-depth understanding of the specific specialty pharma space, coupled with an experienced management and venture investors, has been key to our success."